ArticleAmerican journal of respiratory and critical care medicine2016
Effect of Advanced HIV Infection on the Respiratory Microbiome.
Article in American journal of respiratory and critical care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 95 citations in OpenAlex.
- Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults.Antiviral therapy · 2017Trial
- Trial
- Clinical and microbiota alterations in performance horses undergoing long-distance transport.Journal of veterinary internal medicine · 2026Article
- Microbial DNA analysis of paired blood-bronchoalveolar lavage fluid in post-HSCT patients with pneumonia implying application conditions of blood as a surrogate in pathogen detection.Respiratory research · 2026Article
- Systemic corticosteroids for severe community-acquired pneumonia: a narrative review of mechanisms and critical appraisal of recent trials in ICU.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Analysis of pharyngeal microbiome characteristics in HIV-infected individuals: correlation between the degree of immunosuppression and microbial dysbiosis.BMC infectious diseases · 2026Article
- DeepBiome: A Phylogenetic Tree Informed Deep Neural Network for Microbiome Data Analysis.Statistics in biosciences · 2025Article
- Respiratory microbiota, host immunity, respiratory viral infections and malignant tumors.Frontiers in microbiology · 2025Review
- The lung microbiome in patients with HIV complicated with community-acquired pneumonia: a cross-sectional pilot study.Current research in microbial sciences · 2025Article
- Chronic Obstructive Pulmonary Disease in People with HIV: an Evidence-Based Review.HIV/AIDS (Auckland, N.Z.) · 2025Review
- Lung microbiome: new insights into the pathogenesis of respiratory diseases.Signal transduction and targeted therapy · 2024Review
- Microbial dysbiosis and the host airway epithelial response: insights into HIV-associated COPD using multi'omics profiling.Respiratory research · 2023Article
- The dynamic lung microbiome in health and disease.Nature reviews. Microbiology · 2023Review
- Article
- COPD in People with HIV: Epidemiology, Pathogenesis, Management, and Prevention Strategies.International journal of chronic obstructive pulmonary disease · 2023Review
- MAIT cells and the microbiome.Frontiers in immunology · 2023Review
- Article
- Article
- Alterations in the respiratory tract microbiome in COVID-19: current observations and potential significance.Microbiome · 2022Review
- Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
rationalePrevious work found the lung microbiome in healthy subjects infected with HIV was similar to that in uninfected subjects. We hypothesized the lung microbiome from subjects infected with HIV with more advanced disease would differ from that of an uninfected control population.
objectivesTo measure the lung microbiome in an HIV-infected population with advanced disease.
methods16s RNA gene sequencing was performed on acellular bronchoalveolar lavage (BAL) fluid from 30 subjects infected with HIV with advanced disease (baseline mean CD4 count, 262 cells/mm(3)) before and up to 3 years after starting highly active antiretroviral therapy (HAART) and compared with 22 uninfected control subjects. MEASUREMENTS AND MAIN
resultsThe lung microbiome in subjects infected with HIV with advanced disease demonstrated decreased alpha diversity (richness and diversity) and greater beta diversity compared with uninfected BAL. Differences improved with HAART, but still persisted up to 3 years after starting therapy. Population dispersion in the group infected with HIV was significantly greater than in the uninfected cohort and declined after treatment. There were differences in the relative abundance of some bacteria between the two groups at baseline and after 1 year of therapy. After 1 year on HAART, HIV BAL contained an increased abundance of Prevotella and Veillonella, bacteria previously associated with lung inflammation.
conclusionsThe lung microbiome in subjects infected with HIV with advanced disease is altered compared with an uninfected population both in diversity and bacterial composition. Differences remain up to 3 years after starting HAART. We speculate an altered lung microbiome in HIV infection may contribute to chronic inflammation and lung complications seen in the HAART era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.